Status:
COMPLETED
A Study of LY3541105 in Healthy and Overweight Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Overweight
Healthy
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the b...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical evaluation
- Male participants who agree to refrain from sperm donation and to use contraceptive methods and female participants not of childbearing potential
- Have a body mass index (BMI) in the range of greater than or equal to (\>/=) 18.5 to less than (\<) 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of \>/=27 to \<40 kg/m², both inclusive (in Part B and C)
- Have had a stable weight for the last 3 months
Exclusion
- Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes
- Clinically significant abnormal electrocardiogram (ECG) at screening, as judged by the Investigator
- Have history or current evidence of a clinically significant cardiovascular condition
Key Trial Info
Start Date :
May 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 27 2024
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT05380323
Start Date
May 10 2022
End Date
August 27 2024
Last Update
June 27 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA International
Lenexa, Kansas, United States, 66219
2
ICON Early Phase Services
San Antonio, Texas, United States, 78209